Unknown

Dataset Information

0

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.


ABSTRACT: BACKGROUND:The majority of patients diagnosed with clear cell renal cell carcinoma (ccRCC) have low-risk disease with a < 10% chance of ccRCC-specific death. DNA sequencing revealed that mutations in BAP1 (BRCA1 associated protein-1) occur in 5% to 15% of ccRCC cases and are associated with poor outcomes. The vast majority of BAP1 mutations abolish protein expression. In this study, we used a highly sensitive and specific immunohistochemistry (IHC) assay to test whether BAP1 expression is an independent marker of ccRCC-specific survival, particularly in patients with low-risk disease. METHODS:BAP1 expression was assessed, using IHC, in 1479 patients who underwent nephrectomy to treat clinically localized ccRCC. A centralized pathologist dichotomized patients as either BAP1-positive or BAP1-negative. The authors employed Kaplan-Meier and Cox regression models to associate BAP1 expression with cancer-specific survival. RESULTS:A total of 10.5% of tumors were BAP1-negative, 84.8% of tumors were BAP1-positive, and 4.6% of tumors had ambiguous staining for BAP1. Patients with BAP1-negative tumors have an increased risk of ccRCC-related death (hazard ratio [HR]?= 3.06; 95% confidence interval [CI]?= 2.28-4.10; P = 6.77 × 10(-14) ). BAP1 expression remained an independent marker of prognosis after adjusting for the UCLA integrated staging system (UISS) (HR = 1.67; 95% CI = 1.24-2.25; P

SUBMITTER: Joseph RW 

PROVIDER: S-EPMC4075029 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Joseph Richard W RW   Kapur Payal P   Serie Daniel J DJ   Eckel-Passow Jeanette E JE   Parasramka Mansi M   Ho Thai T   Cheville John C JC   Frenkel Eugene E   Rakheja Dinesh D   Brugarolas James J   Parker Alexander A  

Cancer 20131230 7


<h4>Background</h4>The majority of patients diagnosed with clear cell renal cell carcinoma (ccRCC) have low-risk disease with a < 10% chance of ccRCC-specific death. DNA sequencing revealed that mutations in BAP1 (BRCA1 associated protein-1) occur in 5% to 15% of ccRCC cases and are associated with poor outcomes. The vast majority of BAP1 mutations abolish protein expression. In this study, we used a highly sensitive and specific immunohistochemistry (IHC) assay to test whether BAP1 expression i  ...[more]

Similar Datasets

| S-EPMC6215999 | biostudies-literature
| S-EPMC3974088 | biostudies-other
| S-EPMC10044763 | biostudies-literature
| S-EPMC7539765 | biostudies-literature
| S-EPMC4998678 | biostudies-literature
| S-EPMC8262335 | biostudies-literature
| S-EPMC7880360 | biostudies-literature
| S-EPMC4639322 | biostudies-literature
| S-EPMC4274200 | biostudies-literature
| S-EPMC7237353 | biostudies-literature